Indoco Remedies share news, announcements and annual reports
NSE: INDOCOBSE: 532612Pharmaceuticals & BiotechnologySmall Cap
Indoco Remedies Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2005
Last close ₹208.30down ₹1.20 (0.57%)BSE ₹208.35
Share price at the NSE close on 30 Oct 2026. Previous close ₹209.50.
30 Oct: open ₹208.65, high ₹210.00, low ₹205.10
52-week range of traded prices to 30 Oct 2026
₹162.19Low, 30 Mar 2026₹288.00High, 6 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,923 Cr1,173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 60.20
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.2%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹132 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −10.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.96
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 64,72755.0% delivered
Indoco Remedies share news and announcements
729 announcements, routine notices left out, newest first. Page 13 of 15.
Mar 2014
Feb 2014
Jan 2014
29 Jan · Results
13 Jan · Board meeting
Inter-alia, for taking on record the un-audited financial results for the third quarter ended December 31, 2013.
Dec 2013
Oct 2013
30 Oct · Results
14 Oct · Board meeting
For approval of the unaudited accounts for the Quarter ended 30th September 2013.
Aug 2013
Jul 2013
31 Jul · Disclosure of Voting Pattern - Clause 35A
30 Jul · Results
10 Jul · Board meeting
To approve the Unaudited Results for the Quarter ended 30th June 2013.
Jun 2013
May 2013
28 May · Dividend
Board recommend Payment of dividend of Rs. 1.10 per equity share i.e. 55% for financial year 2012-13.28 May · Dividend
Dividend when approved will be paid on or before 5th August 2013
Apr 2013
18 Apr · Updates
Company has received the approval from United States Food & Drug Administration (USFDA) to manufacture & market GLIMEPIRIDE 1mg, 2mg, & 4mg tablets.
Jan 2013
29 Jan · Board meeting
Board of Directors of the Company at its meeting held on January 29, 2013, has considered the letter of resignation received from Mr. D. M. Sukthankar as Director of the Company and after due deliberations it was decided to accept his resignation.16 Jan · Board meeting
Inter-alia, for taking on record the un-audited financial results for the third quarter ended December 31, 2012.
Nov 2012
29 Nov · Updates
Company has acquired a 60.04% stake in Indoco Industrial Designers & Engineers Private Limited for a consideration of Rs. 22.52 Lacs. The Company is engaged in the business of providing turn key solutions to Pharmaceutical companies for building their plants.
Oct 2012
17 Oct · Board meeting
Inter-alia, for taking on record the un-audited financial results for the second quarter ended September 30, 2012.
Aug 2012
Jul 2012
30 Jul · Results
16 Jul · Board meeting
Inter-alia, for taking on record the un-audited financial results for the first quarter ended June 30, 2012.
May 2012
30 May · Meeting
Annual General Meeting of the Company for the financial year 2011-12 has been fixed for July 30, 2012. Further, the Register of Members and Share Transfer Books of the Company will remain closed from July 24, 2012 to July 30, 2012 (both days inclusive) for the purpose of the payment of dividend for the year ended March 31, 2012 as recommended by the Board and if declared at the Annual General Meeting.29 May · Results
29 May · Dividend
Board of Directors of the Company at its Meeting held on May 28, 2012 has recommended payment of dividend of Rs. 1.10 per equity share on the face value of Rs. 2/- each i.e. 55% for financial year 2011-12 subject to the approval of members in the ensuing Annual General Meeting.16 May · Board meeting
Inter alia, to consider the following : 1) Audited Financial Results for the quarter/year ended on March 31,2012. 2)Recommendation of dividend for the financial year 2011-12,if any ,subject to approval of shareholders in the ensuing Annual General Meeting.9 May · Board meeting
To allot the Bonus Shares.9 May · Corporate action
Board of Directors of the Company has fixed May 19, 2012 as the Record Date for the purpose of: (1) sub-division of shares of Rs.10/- each to Rs. 2/- each.(2) Issue of Bonus shares in the ratio of 1 bonus equity share for every 2 existing equity shares held in the Company.2 May · Board meeting
To approve the following: (1) To fix record date for Sub-division of shares Rs.10/- each to Rs. 2/- each. (2) To fix record date for issue of bonus shares.
Apr 2012